Edition:
India

Cellectis SA (ALCLS.PA)

ALCLS.PA on Paris Stock Exchange

25.90EUR
23 Feb 2018
Change (% chg)

€-0.90 (-3.36%)
Prev Close
€26.80
Open
€26.60
Day's High
€26.60
Day's Low
€25.90
Volume
80,121
Avg. Vol
122,433
52-wk High
€30.00
52-wk Low
€18.20

Select another date:

Tue, Feb 13 2018

France's Cellectis wins U.S patents for gene editing technology

PARIS The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.

France's Cellectis wins U.S patents for gene editing technology

PARIS, Feb 13 The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.

BRIEF-Cellectis, Servier And Pfizer Present Preliminary Data From Two UCART19 Phase I Studies

* SERVIER AND PFIZER PRESENT PRELIMINARY DATA FROM UCART19 PHASE I STUDIES IN ADULT AND PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

BRIEF-Cellectis Appoints Stéphane Depil Senior VP Research & Development And Chief Medical Officer

* CELLECTIS APPOINTS IMMUNO-ONCOLOGY LEADER STÉPHANE DEPIL TO POSITION OF SENIOR VICE PRESIDENT RESEARCH & DEVELOPMENT AND CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Cellectis shares slump as death puts cell therapy tests on hold

LONDON French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment similar to Novartis's recently approved Kymriah, has been forced to suspend testing following a patient death.

BRIEF-Cellectis says FDA places clinical hold of UCART123 studies following fatality

* ANNOUNCED TODAY HAVING RECEIVED NOTICE FROM FDA THAT CLINICAL HOLD WAS PLACED ON BOTH UCART123 ONGOING PHASE 1 STUDIES IN ACUTE MYELOID LEUKEMIA (AML) AND IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)

Select another date: